Cardiovascular disease risk prediction models in the Chinese population - a systematic review and meta-analysis

Guo Zhiting¹, Tang Jiaying¹, Han Haiying², Zhang Yuping¹, Yu Qunfei¹ and Jin Jingfen¹,3*

Abstract

Background: There is an increasing prevalence of cardiovascular disease (CVD) in China, which represents the leading cause of mortality. Precise CVD risk identification is the fundamental prevention component. This study sought to systematically review the CVD risk prediction models derived and/or validated in the Chinese population to promote primary CVD prevention.

Methods: Reports were included if they derived or validated one or more CVD risk prediction models in the Chinese population. PubMed, Embase, CINAHL, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), VIP database, etc., were searched. The risk of bias was assessed with the Prediction Model Risk of Bias Assessment Tool (PROBAST). Meta-analysis was performed in R using the package metanmisc.

Results: From 55,183 records, 22 studies were included. Twelve studies derived 18 CVD risk prediction models, of which seven models were derived based on a multicentre cohort including more than two provinces of mainland China, and one was a model developed based on a New Zealand cohort including Chinese individuals. The number of predictors ranged from 6 to 22. The definitions of predicted outcomes showed considerable heterogeneity. Fourteen articles described 29 validations of 8 models. The Framingham model and pooled cohort equations (PCEs) are the most frequently validated foreign tools. Discrimination was acceptable and similar for men and women among models (0.60–0.83). The calibration estimates changed substantially from one population to another. Prediction for atherosclerotic cardiovascular disease Risk in China (China-PAR) showed good calibration [observed/expected events ratio = 0.99, 95% PI (0.57, 1.70)] and female sex [1.10, 95% PI (0.23, 5.16)].

Conclusions: Several models have been developed or validated in the Chinese population. The usefulness of most of the models remains unclear due to incomplete external validation and head-to-head comparison. Future research should focus on externally validating or tailoring these models to local settings.

Trail registration: This systematic review was registered at PROSPERO (International Prospective Register of Systematic Reviews, CRD42021277453).

Keywords: Cardiovascular diseases, Prediction model, Risk

Background

Cardiovascular disease (CVD) is the leading cause of mortality and a major contributor to disability worldwide, which led to 18.6 million deaths in 2019 [1]. Internationally, China and India have the highest burdens of CVD [2]. There is an increasing prevalence of CVD in
China, where it represents the leading cause of mortality [3, 4].

In an attempt to mitigate the risk and reduce the burden of cardiovascular disease in such a vast country, implementing an overall risk-based prevention approach has been confirmed as a cost-effective method [5, 6]. However, it is critical to know that precise CVD risk identification is the fundamental prevention component [7]. Inappropriate risk-based CVD management may lead to undertreatment or overtreatment. Risk assessment offers a platform for communication between health care providers and patients, improving patients' perception of risk and promoting shared decision-making, which ultimately enhances patients' adherence to medical treatment and health lifestyle modification [8].

Over the past two decades, more than 360 CVD risk prediction models have been developed through one or several longitudinal cohorts since the pioneering Framingham research [9]. However, these equations were mostly derived from Caucasian populations, and population ethnicity and region have roles in modifying cardiovascular risk [10]. As a result, these models cannot be used interchangeably without recalibration because of the different risk factor profiles (i.e., lower level of total cholesterol and higher absolute hypertension burden in China) and CVD profiles (i.e., higher stroke/cardiovascular disease ratio in China) between western and Chinese populations [8]. The Framingham risk equations and American College of Cardiology/American Heart Association Pooled Cohorts Equations (PCEs) were most commonly validated in the Chinese population, with a broad range overestimation in men and underestimation in women [11–14]. Several CVD risk prediction models have been developed based on the large sample size of Chinese adults since 2003, such as the 10-year risk prediction model of CVD in Chinese [15–17], Prediction for atherosclerotic cardiovascular disease Risk in China (China-PAR) [13], and the 5-year risk prediction model of CVD [18]. However, it is not clear which is currently the most appropriate tool for Chinese cardiovascular disease risk prediction.

The aim of this study was to systematically review the published research that derived or validated one or more CVD risk prediction models in China, followed by a formal meta-analysis to summarize and compare the overall predictive performance of these models to inform the choice of the risk model in China.

**Methods**

This systematic review protocol was registered at PROSPERO (International Prospective Register of Systematic Reviews) (CRD 42021277453). We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines published by the Cochrane Prognosis Methods Group [19], and the checklist for systematic reviews and meta-analyses of prediction modelling studies [20] was used to conduct our systematic review.

**Literature search**

For this review, we used the search details of the review by Damen et al. [9] on all CVD prediction models for the general population. In the original search in 2013, two databases (Medline and Embase) were searched. As shown by this review, several CVD prediction models have been developed in recent years. Therefore, we complemented the search details by updating their search and expanding the search database. This search strategy was translated appropriately for Embase, CINAHL, Web of Science (Core Collection), and Scopus. We also developed a Chinese search strategy combining subject indexing terms and free-text search terms in the title and abstract fields in the Chinese Biomedical Literature Service System (SinoMed). This search strategy was translated appropriately for the Wan Fang Database, China National Knowledge Infrastructure (CNKI) and VIP database. A search of Open Grey (OpenGrey, 2019) and Google Scholar was conducted to obtain potential grey literature. The search strategy is presented in Table S1. We systematically searched electronic databases from inception to September 10, 2021. This systematic review was limited to studies conducted in humans and published in English or Chinese. For external validation studies where the development study was not screened by our search, we manually retrieved the original article through citation.

**Eligibility criteria**

We included all primary articles that reported one or more multivariable prediction models or scores that have been suggested for individual risk estimation of any future CVD outcome. However, in the full-text screening, we included only models developed or validated in the Chinese population. We defined ‘model developed in Chinese population’ as 1) the risk models specifically developed to predict CVD in Chinese and 2) the original cohort of model construction including Chinese; moreover, this model can be used in Chinese population CVD risk estimation. For the validation papers, both studies that validated prediction models only in the Chinese population and published validation data containing Chinese were included. The type of model presentation was not limited. Additionally, two or more presented model types yielding the same predictor-outcome associations with some baseline hazard or risk estimate were considered as one model.
We excluded articles without a defined end-point and describing models for predicting the risk of venous disease or stroke alone; validation articles with a cross-sectional study design that, for instance, compared predicted risks of two different models at one time point without any association with actual CVD outcomes; carotid endarterial plaque detected by carotid ultrasound was used as a surrogate of CVD end point event in the studies; studies reporting on the incremental value of one or more new predictors to existing models [9] and investigating a single predictor [21]; and articles describing models developed from or validated exclusively in specific populations, such as patients with diabetes, with HIV, with atrial fibrillation, or undergoing any cardiac surgery.

**Screening process**
Initially, pairs of two trained reviewers (Guo ZT and Tang JY) independently screened retrieved records for eligibility on the title and subsequently on the abstract. Then, the full text of the remaining studies was obtained. The same two reviewers examined potentially relevant studies according to the predetermined eligibility criteria. Disagreements were resolved by discussion with an advisor (Zhang YP).

**Data extraction**
The eligible articles were categorized into two groups: development articles and external validation articles. A standardized electronic form followed by the checklist for appraisal and data extraction for systematic reviews of prediction modelling studies (CHARMS checklist) [22] was constructed to facilitate the data extraction process (Table S2). Information extracted from studies describing model development included study design, location, cohort information, prediction horizon, predicted outcome, predictors, modelling method, method of internal validation, the number of study participants and CVD events, model presentation (e.g., regression equation or risk chart) and predictive performance.

For studies describing external validation of a prediction model, we extracted the study design, prediction model, cohort information, predicted outcome(s), prediction horizon, the number of study participants, observed and expected CVD events, and the model's predictive performance before model recalibration. If an article described multiple models or validated them in different cohorts, we carried out separate data extraction for each model or cohort. We sought clarification from the authors using email communication if important information was missing. In addition, for prediction models with a time-to-event outcome, it is important to note that the extracted values for observed events should be based on Kaplan–Meier estimates [23].

One reviewer (Guo ZT) screened the full-text articles and extracted data from the included studies. A second reviewer (Han HY) checked the exact items. For any disagreements, a third (Zhang YP) reviewer was involved in reaching a consensus.

**Critical appraisal**
We adopted PROBAST to assess the risk of bias from 4 aspects: participants, predictors, outcome and analysis, which can cause distorted estimation of a prediction model's performance; in addition, PROBAST can also evaluate the applicability of a prediction model [22, 23]. The signalling questions were answered as yes, probably yes, probably no, no and no information. The results of risk of bias had 3 potential outcomes: low, high or unclear risk of bias. A positive answer suggests no risk of bias. Two reviewers (Tang JY, Yu QF) independently assessed the methodological quality (risk of bias) and applicability of the included studies. If there were any disagreements, they were resolved by discussion and consultation with an advisor (Jin JF) to reach a consensus.

**Reliability and clinical usability of available models**
Reliability was defined using the following criteria: 1) models validated externally in a separate investigation/paper, 2) C statistic > 0.70 [24], and 3) overestimated/underestimate rate lower than 100% [25]. For reliable models, clinical usability was assessed by 4 items: 1) 10 predictors or fewer, 2) no more than one medical resource needed, 3) full equation or risk chart reported and 4) availability of an online calculator [24, 26]. All eligible models included were evaluated. The mean C statistic and summarized overestimated/underestimate rate were used when more than one validation was reported.

**Statistical analysis**
The pooled c-statistic and OE ratio was performed by meta-analysis for each prediction model. For those articles that did not report the OE ratio, we calculated or estimated it through other data listed in the papers using the equations recommended by Debray et al. [20] Additionally, some studies validated cohorts shorter than 10 years in which these models were initially designed to predict 10-year CVD events; we extrapolated observed event risk (PO) and expected event risk (PE) separately to 10 years using the equation based on Poisson distribution, and observed 10-year cumulative events were calculated through Kaplan–Meier estimates [20, 23]. Furthermore, we stratified the meta-analysis by model and gender. Based on previous recommendations [23], random-effect models with restricted maximum likelihood estimation.
for the pooled C statistic, OE ratio, and approximate 95% prediction intervals were used.

We investigated the heterogeneity among the included studies through sensitivity analysis. Several prespecified sensitivity analyses were performed in which we investigated the influence of risk of bias and case-mix difference (e.g. ethnic group, age range and alternative estimated OE methods) on our findings (Supplementary file). All analyses were implemented in R version 3.10 (R Core Team, Vienna, Austria) using the package metamisc [23].

**Results**

**Study selection and characteristics**
The search strategy identified 55,183 records, of which 26,608 duplicated records and 2983 animal model or in vitro model studies were excluded; then, 25,592 records were screened based on the title and abstract. Two hundred sixty-two records were identified via other methods. In total, 472 full texts were assessed for eligibility, of which 22 studies were included in this review (Fig. 1). Twelve studies [13, 15–18, 27–33] described the development of one or more CVD risk prediction models, and 10 articles [11, 12, 14, 25, 34–39] especially concerned the external validation of one or more risk models. Frequently, four studies [13, 15, 16, 33] described combinations of derived or external validation; therefore, the total number does not sum up to 22. Twenty (90.9%) of the eligible articles were published in English, and 2 reports were written in Chinese.

**Risk of bias**
Most studies were deemed to be of low risk for participant selection and predictors of risk bias. In the outcome domains, the majority of studies reported outcome definitions using ICD codes or WHO criteria, while few studies did not report the outcome definition details. More than half of the validations scored a high risk of bias due to the inadequate handling of missing data. Seven studies scored high concerns of applicability according to inappropriate inclusion criteria, subjectively defined predictors and unclear outcome definitions. A summary of the risk of bias analysis is shown in Fig. 2.

**Development of prediction models**
Ten models were formed in 10 distinct papers [13, 15, 17, 18, 27–31, 33], and two articles reported more than two models [16, 32]. Of these, 11 models were developed in the cohort from one region of China (e.g., Beijing, Zhejiang or China Taiwan); there were 7 models derived based on a multicentre cohort including more than two...
provinces of mainland China (Table 1). In particular, the PREDICT equation [30] was developed based on 400,000 primary care cohorts in New Zealand, including Chinese or other Asian (10.15%) individuals. Fifteen (83.3%) were sex-predictor models. Table 1 shows the year in which the models were published. CVD prediction model development began in 2003 [17], and the latest model was published in 2021 [33]. Thirteen (72.2%) models were published since 2010, while the recruitment year of the cohort had a broad range from 1994 to 2014. The median follow-up time ranged from 3 years to 15.1 years according to the variation in the model prediction horizon. Ten of the selected reports included population-based samples of the general population, whereas 2 studies included people who underwent physical examinations [29] or health management [18], and one study predicted CVD risk for high-risk CVD people [32].

Predictors in the development papers
The number of predictors was 6–22 [IQR: 6.75–11.25]. Age, smoking, sex, SBP, total cholesterol, diabetes, BMI, and high-density lipoprotein were the most commonly used predictors in the development models. However, lifestyle predictors (e.g., drinking, physical activity, action capability) and ECG factors (e.g., heart rate, abnormal electrocardiogram) were considered in a few models. The incidence of fatal and nonfatal cardiovascular events was defined in nine models, but the definitions of these outcomes showed considerable heterogeneity (Table S3); two models from China Taiwan used CVD death as the follow-up outcome [29, 31]. Fourteen models from eight studies predicted 10-year CVD risk, while less than 5-year CVD risk was predicted in three models, and one model predicted lifetime CVD risk. A Cox proportional hazard regression model was performed to model establishment in 10 articles. One article reported the random forest, classification and regression tree (CART), naive Bayes, bagged trees, and AdaBoost methods. Nine (50.0%) models provided full risk equations or risk sheets, in which 2 studies also designed the online calculator based on the risk equation. Regarding model performance, the c-statistic or area under the receiver operating characteristic curve was reported in 11 studies. The median c-statistic was similar at 0.77 [range: 0.67–0.84] in men and 0.78 [range: 0.68–0.89] in women.
| Reference          | Derivation model                  | Recruitment years | Median FU time / Prediction horizon | Study Settings | Derivation cohort size | Internal Validation cohort size / method | Age range | Predictors | Outcomes                  | Modeling Method | Model accessibility | C statistic (95% CI) | Calibration | external validation |
|-------------------|-----------------------------------|-------------------|------------------------------------|----------------|------------------------|------------------------------------------|-----------|------------|----------------------------|-----------------|---------------------|---------------------|-------------|---------------------|
| Wang 2003 [17]    | 10-year Risk model of CVD         | 1992–2002         | 6.1/10y                            | C.MCS          | 31,728                 | No                                       | 35–64     | Age, Gender, TC, SBP, HDL-C, smoking, FG | Fatal or non-fatal CVD | COX regression       | Male 0.78 (0.76–0.81) | Female 0.76 (0.72–0.80) | NR          | NO                  |
| Liu 2004 [15]     | CHD risk model                    | 1992–1993, 1996–1999 | 10/10y                             | C.MCS          | 30,121                 | No                                       | 35–64     | Age, Gender, TC, BP, HDL-C, smoking, DM | Fatal CHD      | COX regression       | Male 0.76 (0.70–0.82) | Female 0.74 (0.70–0.78) | Hosmer-Lemeshow test | NO                  |
| Zhang 2005 [27]   | 10-year CVD risk prediction score | 1974–1980         | 13.5/10y                           | Beijing        | 3000                   | 1400/ random split-sample                | 18–74     | Age, SBP, DBP, TC, BMI, smoking         | Fatal or non-fatal CVD | COX regression       | CHD events training dataset 0.76/ validation dataset 0.76; IS events training dataset 0.72/ validation dataset 0.78 | Hosmer-Lemeshow test | No                  |
Table 1 (continued)

| Reference  | Derivation model | Recruitment years | Median FU time / Prediction horizon | Study Settings | Derivation cohort size | Internal Validation cohort size/ method | Age range | Predictors | Outcomes | Modeling Method | Model accessibility | C statistic (95% CI) | Calibration | external validation |
|------------|------------------|-------------------|-------------------------------------|----------------|------------------------|----------------------------------------|-----------|------------|----------|----------------|-------------------|---------------------|-------------|---------------------|
| Wu 2006 [16] | 10-year Risk prediction model of ICVD | 1983–1984 | 15.1/10y | USA PRC cohort | 9903 | No | 35–59 | Age, Gender, SBP, TC, BMI, smoking, DM | Fatal or non-fatal CVD | COX regression | Yes/Risk Sheet/online calculator | Optimal model: male 0.80 (0.76–0.83)/female 0.79 (0.76–0.83); simplified model: male 0.79 (0.76–0.83)/female 0.78 (0.75–0.82) | Hosmer–Lemeshow test | Yes |
| Yang 2016 [13] | China-PAR cardiovascular and other risk factors | 1998–2000 | 12.3/10y | InterASA MUCA (1998) | 21,320 | 21,320/10*10 cross-validation | 35–74 | Age, Gender, SBP/Rx, TC, HDL-C, smoking, DM, WC, GR, FHAC, Urbanization | Fatal or non-fatal CVD | COX regression | Yes/Online calculator | Male 0.79 (0.78–0.81)/Female 0.81 (0.79–0.82) | Hosmer–Lemeshow test and slope | Yes |
| Hu 2017 [29] | Cardiovascular death prediction model | 1994 | 8.8/10y | Taiwan | 381,963 | No | 20+ | Age, Gender, BMI, smoking, physical activity, anemia, SBP, FG, TC, HDL, LDL, proteinuria, uric acid, CKD, CRP, heart rate, hypertension treatment | CVD death | COX regression | No | 0.91 (0.90–0.92) | NR | No |
| Reference          | Derivation model                  | Recruitment years | Median FU time / Prediction horizon | Study Settings | Derivation cohort size | Internal Validation cohort size / method | Age range | Predictors | Outcomes          | Modeling Method | Model accessibility | C statistic (95% CI) | Calibration external validation |
|-------------------|-----------------------------------|-------------------|-------------------------------------|----------------|------------------------|------------------------------------------|------------|------------|-------------------|------------------|---------------------|----------------------|-------------------------|
| Li 2017 [18]     | Risk prediction model of CVD      | 2004              | 3.09/5y                             | Shandong       | 50,990                 | 21,853/10*10 cross-validation            | 20+        | Age, Gender, BMI, DM, CKD, abnormal electrocardiogram, smoking, hypertension, dyslipidemia | Fatal or non-fatal CVD COX regression NO | Training dataset: male 0.84 (0.82–0.85)/ Female 0.90 (0.88–0.91) Validation dataset: male 0.84 (0.81–0.86)/ female 0.89 (0.87–0.91) | NR                  | No                     |
| Pylypchuk 2018 [30] | PREDICT equations              | 2002              | 4.2/5y                             | New Zealand    | 401,752                | 166,611/ geographical split-sample     | 30–74      | Age, Gender, NZDep, smoking history, diabetes, SBP, TC/HDL, OBPLM | Fatal or non-fatal CVD COX regression Yes/Risk equations | Male 0.73 (0.72–0.73)/ Female 0.73 (0.72–0.73) | Calibration slope No |                       |
| Li 2020 [31]     | Risk prediction model of CVD      | 2004              | 10/10y                             | Taiwan         | 1481                   | 740/bootstrap resampling               | 40+        | Age, Gender, Marital status, BMI, smoking, physical activity, eGFR, ACR, history of heart disease, history of stroke, ABI | Fatal or non-fatal CVD COX regression NO | 0.88 (0.83–0.93) Hosmer–Lemeshow test |                       | No                     |
| Reference | Derivation model | Recruitment years | Median FU time / Prediction horizon | Study Settings | Derivation cohort size | Internal Validation cohort size/ method | Age range | Predictors | Outcomes | Modeling Method | Model accessibility | C statistic (95% CI) | Calibration | external validation |
|-----------|------------------|-------------------|-----------------------------------|----------------|------------------------|----------------------------------------|-----------|------------|----------|----------------|---------------------|-------------------|------------|---------------------|
| Yang 2020 [32] | CVD prediction model for high-risk CVD population | 2014 | 3/3y | Zhejiang | 19,953 | 9977/?random split-sample | 35+ | Age, Gender, Family income, smoking drinking, obesity, WC, TC, TG, LDL, FG, action capability, Self-care ability, Daily activity ability, pain, anxiety, History of hypertension/diabetes/dyslipidemia, Family history of hypertension/ ischemic stroke and cerebral infarction, Hypoglycemic drugs use | CVD events | Random forest/ CART/ multivariate regression/ NaiveBayes/ Bagged trees/Ada Boost | No | optimal model (random forest) from 6 models: Male 0.82/ female 0.68 |
| Huang2021 [33] | GBCS prediction model | 2003–2008 | 12/10y | China/ Guangzhou | 15,000 | 12,721/10*10 cross-validation | 50+ | Age, Gender, SBP, antihypertensive medication use, ever smoking, and diabetes status | Fatal or non-fatal CVD | COX regression | Yes/Risk equations | Training dataset: male 0.69 (0.67– 0.71)/ female 0.73 (0.71– 0.74) Validation dataset: male 0.67 (0.65– 0.70)/ female 0.72 (0.70– 0.73) |
| Wang 2015 [28] | CVD lifetime risk model | 1992 | 18/lifetime | CMCS | 21,953 | No | 35–84 | SBP/DBP, non-HDL-C, HDL-C, BMI, Diabetes, Smoking | Fatal or non-fatal CVD | Kaplan-Meier method | Yes/Risk sheet | NR | NR | No |

CVD Cardiovascular disease, CMCS Chinese multi-provincial cohort study, TC Total cholesterol, SBP Systolic blood pressure, HDL-C High-density lipoprotein cholesterol, FG Fasting blood-glucose, NR Not reported, CHD Coronary heart disease, BP Blood pressure, DM Diabetes mellitus, DBP Diastolic blood pressure, BMI Body mass index, ICDV Ischemic cardiovascular disease, USA-PRC USA–People’s Republic of China, CHD-PAR Prediction for atherosclerotic cardiovascular disease in China, InterASIA International collaborative study of cardiovascular disease in Asia, MUCA China Multi-Center Collaborative Study of Cardiovascular Epidemiology, WC Waist circumference, GR Geographic region, FHAC Family history of ASCVD, LDL Low-density lipoprotein, CKD Chronic kidney disease, CRP C-reactive protein, eGFR Estimated Glomerular filtration rate, ACR Albumin-to-creatinine ratio, ABI Ankle–brachial index, TG Triglyceride, CART Classification and regression tree, NZDep New Zealand Index of Socioeconomic Deprivation, OBPLM On blood pressure-lowering medications, GBCS Guangzhou Biobank cohort study. a: Chinese article
The Hosmer–Lemeshow test was the most frequently reported in model calibration, and 5 studies did not report model calibration performance. Internal validation was conducted in 6 studies, most often using a random split of the dataset. Only 2 models were validated in an external cohort.

External validation of prediction models
A total of 14 studies described 29 validations of 8 models (Supplementary Table 4). Four models were validated more than two times, including Pooled Cohort Equations Goff 2013 \((n=11)\) validations, China-PAR 2016 \((n=6)\), Framingham D’Agostino 2008 \((n=5)\) and Framingham Wilson \((n=2)\) (Table 2). Of the 8 validated models, three models were fully derived in the cohort from China, and 5 models were outside of China. All these models were validated in Chinese and the area, including provinces from mainland China and Hong Kong. Additionally, two studies validated the model in Malaysian Chinese [34, 35] and one in Chinese American [36]. The c-statistic was reported in all the validation studies and ranged from 0.60 to 0.83. While the observed/expected (OE) ratio was reported in a few studies, four studies only reported Hosmer–Lemeshow test values.

Summary of the predictive performance of the externally validated model
We quantitatively synthesized four models validated more than once, and the performance of four models (i.e., WHO chart for East Asia [40], Asian risk model) that was validated only one time is shown in Table S4.

Calibration
Figure 3 shows the summarized estimated calibration of the three models across genders. For the PCE, we excluded 3 validations using the PCE African American model because the AHA guideline [41] advises using the white model for Chinese people, and one validation did not validate separately among genders. Thus, we quantitatively synthesized 7 validations using PCE white. The PCE model showed overprediction in men and underprediction in women with a large range of prediction intervals. For the Framingham D’Agostino model, the number of observed events was lower than the number of predicted events in men and vice versa in women. However, the summarized prediction performance was worst in Framingham Wilson (O/E ratio 0.27 for men and

| Table 2: Characteristics of validations of included studies |
|-----------------------------------------------------------|
| Framingham Wilson 1998 | Framingham D’Agostino 2008 | PCE Stone 2013 | WHO charts for east Asia & WHO2019 | WHO chart for east Asia & WHO2019 | Asian equation & Asia 2007 | China-PAR & WHO2019 | Risk model (Optimal) & Wu 2006 | Risk model (Simplified) & Wu 2006 |
|--------------------------|-----------------------------|----------------|-----------------------------------|-----------------------------------|-----------------------------|--------------------------|--------------------------|--------------------------|
| Location of the validation cohorts | Framingham Wilson 1998 | Framingham D’Agostino 2008 | PCE Stone 2013 | WHO charts for east Asia & WHO2019 | Asian equation & Asia 2007 | China-PAR & WHO2019 | Risk model (Optimal) & Wu 2006 | Risk model (Simplified) & Wu 2006 |
| Single-province in mainland China | 0 | 3 | 2 | 0 | 0 | 4 | 0 | 0 |
| Multi-province in mainland China | 2 | 0 | 6 | 2 | 1 | 2 | 1 | 1 |
| China Hong Kong | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Ethic Chinese | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Participant age in the validation cohorts | Framingham Wilson 1998 | Framingham D’Agostino 2008 | PCE Stone 2013 | WHO charts for east Asia & WHO2019 | Asian equation & Asia 2007 | China-PAR & WHO2019 | Risk model (Optimal) & Wu 2006 | Risk model (Simplified) & Wu 2006 |
| Min, Median | 30 | 30 | 35 | 40 | 30 | 35 | 35 | 35 |
| Max, Median | 75 | 74 | 79 | 80 | 75 | 74 | 59 | 59 |
| Size of the Validation cohorts | Framingham Wilson 1998 | Framingham D’Agostino 2008 | PCE Stone 2013 | WHO charts for east Asia & WHO2019 | Asian equation & Asia 2007 | China-PAR & WHO2019 | Risk model (Optimal) & Wu 2006 | Risk model (Simplified) & Wu 2006 |
| Sample size, median [range] | 27,901 [25,682–30,121] | 7157 [438–27,721] | 20,886 [425–70,838] | 23,329 [27,321–29,337] | 25,682 [3347–70,838] | 21,631 [15,100–15,100] | 15,100 [347–1091] | 15,100 [347–1091] |
| Events, median [range] | 366 [191–542] | 880 [45–3732] | 622 [21–1493] | 1070 [1045–1091] | 542 [190–1091] | 1209 [347–1091] | 347 [190–3732] | 347 [190–3732] |
| Recruitment years of the Validation cohorts | Framingham Wilson 1998 | Framingham D’Agostino 2008 | PCE Stone 2013 | WHO charts for east Asia & WHO2019 | Asian equation & Asia 2007 | China-PAR & WHO2019 | Risk model (Optimal) & Wu 2006 | Risk model (Simplified) & Wu 2006 |
| < 2000 year | 2 | 2 | 6 | 2 | 1 | 1 | 1 | 1 |
| 2001–2010 year | 0 | 2 | 4 | 0 | 0 | 5 | 0 | 0 |
| > 2010 year | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |

* one validation for WHO lab and non-lab respectively; b model derived in Chinese cohort
0.50 for women) compared to other models, which was not shown in the forest plot due to insufficient articles. China-PAR, as a model derived in Chinese, underestimated CVD risk in men and women with a relatively narrow range, similar to the 10-year risk prediction model of ICVD by Wu et al. 2006.

**Discrimination**

The discriminative performance was similar among the eight models. The performance was slightly better for women than for men among the three pooled models (Fig. 4). The pooled prediction performance was better in models derived from Chinese or Asian populations than in those from Western cohorts (Table S4).

**Sensitivity analysis**

Sensitivity analyses revealed no effect of study quality on the pooled performance of the models, both for calibration and discrimination. The discrimination for the PCE model decreased after excluding studies with less than 10-year cohorts, while the China-PAR and Framingham D’Agostino model showed no effect. We
conducted sensitivity analysis for the PCE model after distinguishing the ethics group of participants in validation studies, and the results showed no effect on calibration but reduced discrimination after excluding the American Chinese cohort. Considering that the model performance may be influenced by the age range of the included participants, we conducted sensitivity analysis after excluding the study by Huang et al. [33] (the lower limit was more than 10 years higher, 50 years vs. 35 years). The results showed improved performance both for calibration and discrimination, as shown in Figs. S1, S2, S3 and S4.

Reliability and clinical usability of available models
All 23 models derived or validated in the Chinese population were first assessed for reliability according to the criteria mentioned before. Six models (26.1%) met these criteria and were considered reliable (Table S5). Then, these models were assessed for clinical usability through 4 aspects. The Framingham D’Agostino model and PCE
had the highest usability score as they met all criteria. China-PAR had high usability with an online calculator with 11 predictors. Other models, such as WHO charts, had higher usability than the Asian equation since the risk chart was more convenient than the equation.

**Discussion**

**Summary of evidence**

Although many cardiovascular disease prediction models have been developed at home and abroad [9, 10], none of them systematically review the applicability and performance of the model among the Chinese, which causes some confusion in clinical practice. Our work complements this evidence from model development and external validation aspects. Finally, twenty-two studies were eligible, of which 18 models were developed, and 3 models also conducted external validation; 5 models were derived from foreign countries validated in Chinese. The Framingham and the PCEs are the most studied tools. China-PAR has been externally validated most frequently as one of the models derived from Chinese. Additionally, the WHO lab or nonlab-based charts for East Asia and Asia cardiovascular risk prediction tools were validated only once. Discrimination was acceptable and similar for men and women among these models. The calibration estimates changed substantially from one population to another. The China-PAR showed good calibration both in men and women, while the Framingham Wilson model showed serious overestimation. Five external models were validated less than two times, so we could not compare them and draw absolute conclusions.

**Model development and validation**

A number of studies developed new risk prediction models for cardiovascular disease in China, although 72.2% of the models were published after 2015. As we know, most models were developed in the European and Northern American populations [9], and it is urgent and necessary to construct a risk prediction model based on the Chinese population to guide CVD prevention in China. However, we found much variability in age range, predictors, and predicted outcomes among development studies. With respect to the outcome definitions, we found similar manifestations with whole risk prediction models worldwide [9]. The heterogeneity of definition for fatal or nonfatal CVD between studies was significant, while different definitions may lead to disparate estimated prediction effects and consequently indicate various treatment strategies based on these models [6]. Thus, this discourages head-to-head comparisons or quantitative integrations between studies, as well as clinical applications. New studies reporting on prediction models should adhere to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines [42, 43] to guarantee uniformity.

We also found an exciting phenomenon that an increasing number of risk prediction models derived from international populations contain Chinese, for instance, WHO risk charts based on 85 international cohorts [40] and PREDICT equations developed for 182 countries [30]. This gave more options for CVD risk prediction in China. However, the number of validation studies in the Chinese population is not sufficient, and we could not draw firm recommendation conclusions for any of them. We advise that more validation studies exist of these models to enrich the evidence.

In addition, internal and external validation are both important for modelling studies. Approximately half of the models conducted internal validation, whereas rare external validations were conducted. This suggested that we made a great effort to develop new models rather than validate, tailor, and improve existing CVD risk prediction models. In contrast, external validation is needed to ensure the transportability of a prediction model. Although two Chinese models were externally validated in another Chinese cohort, CVD risk varies geographically, and the major contributing risk factors were different across regions in China (i.e., a higher hypertension ratio in northern China, lowest ratio of metabolic and physical activity in northwestern China and lowest ratio of smoking and alcohol in northeastern China) [44]. This means that one model derived from a single region is imprecise for evaluating the real risk in another area. Despite China-PAR being derived from two multiprovince cohorts, it still overestimated the real risk of the Inner Mongolia population or the elderly in the validation studies [33, 39]. However, pooled C statistics and the estimated OE ratio indicated the good performance of the China-PAR in China. This result indicates that the China-PAR may be a better choice for CVD risk prediction in China. Compared with the performance of Framingham prediction models in previous studies [45], we found similar results that both Framingham Wilson and Framingham D’Agostino overestimate cardiovascular disease risk. Furthermore, we also found that the Framingham D’Agostino overestimated the cardiovascular disease risk in men and underestimated it in women. This tendency was also found in PCE. Thus, the applicability of these two models in clinical practice was limited by their calibration.

In addition, the sensitivity analysis showed reduced discrimination after excluding the American Chinese cohort for the PCE model, and PCE derived from the multi-ethnic population could be a potential reason. We extrapolated the OE ratio to 10 years using the equation based on Poisson distribution [20] for studies with a prediction
horizon less than 10 years, and sensitivity analysis was performed after excluding these extrapolated studies to clarify this estimation on the pooled performance of these models. The results indicated that the characteristics of the validation cohort should be comparable with the derived cohort to improve the accuracy of prediction.

**Implications for clinical practice**
A number of guidelines have recommended that cardiovascular prevention and treatment be based on risk assessment [41, 46]. The clinical usability of the risk prediction model requires not only acceptable external validation performance but is also easy to use, such as the accessibility of predictors and the availability of a full regression equation or online calculators [24]. However, there are no well-established reliability and clinical usability evaluation tools for prediction models. We designed three criteria for reliability and four criteria for clinical usability according to expert consultation based on previous studies by Baart SJ et al. [24] and Barzi F et al. [25]. Of all 23 models, only 6 (26.1%) models met the reliability criteria. When further evaluated for clinical usability, only the Framingham D’Agostino and PCE models met all criteria, rendering them more appealing for clinical practice. The China-PAR model derived from the Chinese population was recommended by several Chinese CVD prevention guidelines and met all criteria apart from fewer than 10 predictors (11 predictors). Future research should focus on externally validating these three models or tailoring these models to local settings to gain better prediction performance.

**Limitations**
This study has several limitations. First, we had to rely on the reports of authors for primary validation studies, and therefore we had to exclude relevant validations from the final meta-analysis because we could not obtain unreported information from the authors. We excluded two validations in the pooled performance analysis of the Framingham model and one validation of the PCE model, which makes it difficult to argue whether the predictive performance of models will change or not when all validations are included. Second, the number of observed and expected events and the total participant numbers were needed to estimate the pooled OE ratio. Two validations only reported bar charts of predicted or actual events by 10 deciles of predicted risk. We had to infer the OE ratio of each decile through the prediction chart without proofreading the authors. Furthermore, we performed a sensitivity analysis for China-PAR to verify the stability of the results when excluding those inferred validations. The same analysis was not conducted in the Framingham D’Agostino model because of the lower number of validations. Third, we did not perform meta-regression analysis to explore potential heterogeneity factors for each model due to the limitation of the number of validation studies. Generally, at least 10 reports were needed for meta-regression to obtain valid results [20]. Thus, we investigated the heterogeneity through prespecified sensitivity analyses investigating the influence of risk of bias and case-mix difference on our findings. Fourth, we initially evaluated reliability and clinical usability for available models based on criteria designed based on previous publications and expert consultation owing to the lack of well-established tools reported. This may affect the assessment accuracy and requires further study. Fifth, we did not search the publications in languages apart from English and Chinese because of limited resources, which may lead to potential bias for the study findings.

**Conclusions**
In conclusion, there is an increasing trend for cardiovascular disease prediction models developed and validated in the Chinese population, but the validation study was still insufficient. Only the pooled estimated calibration and discrimination of Framingham D’Agostino, PCE and China-PAR were calculated due to the insufficient number of validated model studies, of which China-PAR showed better performance than the other two models. Thus, the usefulness of most CVD prediction models remains unclear due to incomplete external validation and head-to-head comparison based on current search strategies. Future research should focus on externally validating or tailoring these models to local settings.

**Abbreviations**
CVD: Cardiovascular disease; CNKI: China National Knowledge Infrastructure; PROBAST: Prediction Model Risk of Bias Assessment Tool; PCE: Pooled cohort equations; China-PAR: Prediction for atherosclerotic cardiovascular disease Risk in China; PROSPERO: International prospective register of systematic reviews; PRISMA: Preferred reporting items for systematic reviews and meta-analyses; CHARMS checklist: Checklist for appraisal and data extraction for systematic reviews of prediction modelling studies; OE: Observed expected; SBP: Systolic blood pressure; BMI: Body mass index; ECG: Electrocardiogram, CART: Classification and regression tree; TRIPD: Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12889-022-13995-z.
analyses considering less than 10-year prediction horizons (A and B). China-PAR and PEC validations both excluded studies by Yang 2016(CIMC cohort), Jiang 2020 and Tang 2019. Framingham D’Agostino model validations excluded studies by Jiang 2020. PCE: Pooled Cohorts Equations, OE: observed expected. Fig. S3: Sensitivity analyses considering age group for China-PAR model (A and B). OE: observed expected. Fig. S4. Sensitivity analyses considering ethnic group for PCE model. PCE: Pooled Cohorts Equations, OE: observed expected.

Acknowledgements
None.

Authors’ contributions
Study design: Guo Zhiting and Jin Jingfen. Literature research and screen: Guo Zhiting and Tang Jiaying. Data extraction: Guo Zhiting and Han Haiying. Critical appraisal: Tang Jiaying and Yu Qunfei. Evidence assessment: Zhang Yuping and Han Haiying. Statistical analysis: Guo Zhiting. Manuscript writing: Guo Zhiting and Jin Jingfen. The author(s) read and approved the final manuscript.

Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Availability of data and materials
All data analysed during this study are included in this article and its supplementary information files.

Declarations

Ethics approval and consent to participate
This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

Consent for publication
All authors approve the manuscript for publication.

Competing interests
The authors declare that they have no conflicts of interest.

Author details
1 Nursing Department, The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU), No.88 Jiefang road, Shangcheng District, Hangzhou 310009, Zhejiang Province, China. 2 Zhejiang University City College, No. 51 Huzhou Street, Gongshu District, Hangzhou 310015, Zhejiang Province, China. 3 Key Laboratory of The Diagnosis and Treatment of Severe Trauma and Burn of Zhejiang Province, Hangzhou 310009, Zhejiang Province, China.

Received: 24 March 2022 Accepted: 10 August 2022
Published online: 24 August 2022

References
1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Badour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
2. Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203–12.
3. Liu S, Li Y, Zeng X, Wang H, Yin P, Wang L, et al. Burden of cardiovascular diseases in China, 1990-2016: findings from the 2016 global burden of disease study. JAMA Cardiol. 2019;4(4):342–52.
4. China TWCoRChDaIC. Key points of report on cardiovascular health and disease in China 2020. Chinese journal of Cardiovasc Res. 2021;19(9):582–90.
5. Wei X, Walley JD, Zhang Z, Zou G, Gong W, Deng S, et al. Implementation of a comprehensive intervention for patients at high risk of cardiovascular disease in rural China: a pragmatic cluster randomized controlled trial. PLoS One. 2017;12(8):e0183169.
6. Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC, Jr, Sperling LS, Virani SS, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. Circulation. 2019;139(25):e1162–e77.
7. Wong ND. Cardiovascular risk assessment: the foundation of preventive cardiology. Am J Prev Cardiol. 2020;1:100008.
8. Zhang Y, Miao H, Chia YC, Buranakitjaroen P, Siddique S, Shin J, et al. Cardiovascular risk assessment tools in Asia. J Clin Hypertens (Greenw). 2022;24(4):369–77. https://pubmed.ncbi.nlm.nih.gov/34981620/.
9. Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I, et al. Predictors in cardiovascular disease risk models in the general population: systematic review. BMJ. 2016;353:i2416.
10. Gopal DP, Usher-Smith JA. Cardiovascular risk models for south Asian populations: a systematic review. Int J Public Health. 2016;61(5):525–34.
11. Tang X, Zhang D, Li L, Wu N, Si Y, Cao Y, et al. Performance of atherosclerotic cardiovascular disease prediction models in a rural northern Chinese population: results from the Fangshan cohort study. Am Heart J. 2019;211:34–44.
12. Jiang Y, Ma R, Guo H, Zhang X, Wang X, Wang K, et al. External validation of three atherosclerotic cardiovascular disease risk equations in rural areas of Xinjiang, China. BMC Public Health. 2020;20(1):1471.
13. Yang X, Li J, Hu D, Chen J, Li Y, Huang J, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (prediction for ASCVD risk in China). Circulation. 2016;134(19):1430–40.
14. Peng H, Jiao Y, Zeng Q, Li H, Zhang M, Wang A, et al. Utility of Framingham general cardiovascular disease risk score for predicting 10-year cardiovascular risk in an inner Mongolian population: a prospective cohort study. Int J Cardiol. 2014;172(1):274–5.
15. Liu J, Hong Y, D’Agostino RB Sr, Wu Z, Wang W, Sun J, et al. Predictive value of the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. JAMA. 2004;291(21):2591–9.
16. Wu Y, Liu X, Li X, Li Y, Zhao L, Chen Z, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation. 2006;114(21):2217–25.
17. Wang W, Zhao D, Liu J, Wu G, Zeng Z, Liu J, et al. Prospective study on the predictive model of cardiovascular disease risk in a Chinese population aged 35–64. Chin J Cardiol. 2003;31(12):902–8.
18. Li J, Zhao H, Song B, Zhang L, Li X, Chen Y, et al. Risk prediction model of cardiovascular disease based on health management cohort. J Shandong Univ (Health Science). 2017;5(6):56–65.
19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:t372.
20. Debray TP, Damen JA, Snell K, Ensor J, Hooft L, Reitsma JB, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ. 2017;356:i6460.
21. Zhang H, Shao J, Chen D, Zou P, Cui N, Tang L, et al. Reporting and methods in developing prognostic prediction models for metabolic syndrome: a systematic review and critical appraisal. Diabetes Metab Syndr Obes. 2020;13:4981–92.
22. Moons KG, de Groot JA, Bouwmeester W, Vergouw E, Mallett S, Altman DG, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMs checklist. PLoS Med. 2014;11(10):e1001744.
23. Debray TP, Damen JA, Riley RD, Snell K, Reitsma JB, Hooft L, et al. A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes. Stat Methods Med Res. 2019;28(9):2768–86.
24. Baart SJ, Dam V, Scheres LJJ, Damen JA, Spieker R, Schuit E, et al. Cardiovascular risk prediction models for women in the general population: a systematic review. PLoS One. 2019;14(11)e0210329.
25. Asia Pacific Cohort Studies C, Barzi F, Patel A, Gu D, Sritara P, Lam TH, et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health. 2007;61(2):115–21.
26. Shelton R. The emergency severity index 5-level triage system. Dimens Crit Care Nurs. 2009;28(1):9–12.

27. Zhang XF, Attia J, D’Este C, Yu XH, Wu XG. A risk score predicted coronary heart disease and stroke in a Chinese cohort. J Clin Epidemiol. 2005;58(9):951–8.

28. Wang Y, Liu J, Wang W, Wang M, Qi Y, Xie W, et al. Lifetime risk for cardiovascular disease in a Chinese population: the Chinese multi-provincial cohort study. Eur J Prev Cardiol. 2015;22(3):380–8.

29. Hu WS, Lee JH, Tsai MK, Wen CP. A novel cardiovascular death prediction model for Chinese individuals: a prospective cohort study of 381,963 study participants. Atherosclerosis. 2017;264:19–28.

30. Pylypchuk R, Wells S, Kerr A, Poppe K, Riddell T, Harwood M, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet. 2018;391(10133):1897–907.

31. Li TC, Li CI, Liu CS, Lin Wy, Lin CH, Yang SY, et al. Derivation and validation of 10-year all-cause and cardiovascular disease mortality prediction model for middle-aged and elderly community-dwelling adults in Taiwan. PLoS One. 2020;15(9):e0239063.

32. Yang L, Wu H, Lin X, Zheng P, Hu S, Xu X, et al. Study of cardiovascular disease prediction model based on random forest in eastern China. Sci Rep. 2020;10(1):5245.

33. Huang YY, Tian WB, Jiang CQ, Zhang WS, Zhu F, Jin YL, et al. A simple model for predicting 10-year cardiovascular risk in middle-aged to older Chinese: Guangzhou biobank cohort study. J Cardiovasc Transl Res. 2022, 15(2):416–26. https://pubmed.ncbi.nlm.nih.gov/34402029/.

34. Chia YC, Gray SY, Ching SM, Lim HM, Chinning K. Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study. BMJ Open. 2015;5(5):e007324.

35. Chia YC, Lim HM, Ching SM. Validation of the pooled cohort risk score in an Asian population - a retrospective cohort study. BMC Cardiovasc Disord. 2014;14:163.

36. DeFilippis AP, Young R, McEvoy JW, Michos ED, Sandfort V, Kronmal RA, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38(8):598–608.

37. Lee CH, Woo YC, Lam JK, Fong CH, Cheung BM, Lam KS, et al. Validation of the pooled cohort equations in a long-term cohort study of Hong Kong Chinese. J Clin Lipidol. 2015;9(5):640–6 e2.

38. Li J, Liu F, Yang X, Cao J, Chen S, Chen J, et al. Validating World Health Organization cardiovascular disease risk charts and optimizing risk assessment in China. Lancet Reg Health-Western Pacific. 2021;8:100096.

39. Zeng NM, Zheng XW, Peng H, Jiao Y, Li HM, Zhang MZ, et al. Validation of the China-PAR equations for cardio-cerebrovascular risk prediction in the inner Mongolian population. Biomed Environ Sci. 2018;31(6):463–6.

40. Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332–e45.

41. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–59.

42. Leisman DE, Harhay MO, Lederer D, Abramson M, Adjei AA, Bakker J, et al. Development and reporting of prediction models: guidance for authors from editors of respiratory, sleep, and critical care journals. Crit Care Med. 2020;48(5):623–33.

43. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPDM). Ann Intern Med. 2015;162(10):735–6.

44. Li X, Wu C, Li J, Chen B, Li Y, Yang Y, et al. Cardiovascular risk factors in China: a nationwide population-based cohort study. Lancet Public Health. 2020;5(12):e672–81.

45. Darren JA, Pajouheshnia R, Heus P, Moons KGM, Reitsma JB, Scholten R, et al. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 2019;17(1):109.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.